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and IL-21 contribute to the pathogenesis of IgG4-DS, specifically facilitating the production of IgG4 and formation of ectopic germinal centers 7, 8 . It should be noted that the abovementioned studies were conducted on salivary glands (SGs) from patients with IgG4-DS; however, the SG samples from these patients have high frequencies of typical IgG4-RD characteristics and are indicated as an ideal pathological manifestation of IgG4-RD 9, 10 . Together, these studies have revealed that the main pathogenesis of IgG4-RD is related to Th2 cell and cytokine activation 11, 12 .
To our knowledge, no published reports have investigated the mechanism of Th2 cell activation in IgG4-RD. Recently, IL-33, a member of the IL-1 cytokine family, has been shown to accelerate Th2 cell expression of the IL-33 receptor, ST2 13 . In vitro, IL-33 directly stimulates Th2 cells, mast cells, eosinophils, and basophils, resulting in Th2 cytokine production 14 . Several studies have reported that IL-33 has important biological functions in several immune-mediated diseases such as asthma, allergic rhinitis, cardiovascular disease, multiple sclerosis, rheumatoid arthritis, and SS [15] [16] [17] [18] [19] . Moreover, IL-33 is produced by epithelial cells, macrophages, dendritic cells (DCs), and mast cells 13 . In humans, at least two types of macrophages and DCs have been identified based on their function and reaction. The macrophages include the classically activated macrophage (M1), which is activated via CD68 + CD163 − , and the alternatively activated macrophage (M2), which is activated via CD68 + CD163 +20 . The DCs include myeloid DC (mDC), which is activated by CD11c high CD123 low , and plasmacytoid DC (pDC), which is activated by CD11c − CD123 high 21 . Recent reports have indicated that the M1 macrophage is capable of stimulating the Th1 response via IL-6 and IFN-γ . Alternatively, the M2 macrophage is stimulated by the Th2 response, and promotes the Th2 reaction through IL-13 production 22, 23 . Further, mDCs likely exert inhibitory effects on the development of Th1 inflammatory responses, while pDCs inhibit Th2 inflammatory responses 24 . However, the relationship between macrophages, DCs, and IgG4-RD has not yet been elucidated. Therefore, to clarify the contribution of IL-33 to the pathogenesis of IgG4-RD, we examined infiltrating cells expressing IL-33 in SGs from patients with IgG4-RD.
Materials and Methods
Ethics Statement. The study design and methods were approved by the Institutional Review Board of Center for Clinical and Translational Research of Kyushu University Hospital (IRB serial number: 25-287). The methods were carried out in accordance with the approved guidelines. All patients or their relatives gave their informed consent within written treatment contract on admission and therefore prior to their inclusion in the study.
Study Participants. SG samples were collected from patients referred to the Department of Oral and Maxillofacial Surgery, Kyushu University Hospital between 2010 and 2014. Seven patients with IgG4-RD (five men and two women; mean age ± standard deviation (SD), 61.7 ± 12.1 years), 10 with primary SS (five men and five women; 55.6 ± 20.5 years), and 10 with oral squamous cell carcinoma (OSCC) as a control group (five men and five women; 58.4 ± 16.3 years) participated in this study. Clinical and serological profiles of patients with IgG4-RD are listed in Table 1 .
Patients with IgG4-RD and SS underwent open SG biopsies, as described by Moriyama et al. 20 , while patients with OSCC underwent a neck dissection. SGs from patients with OSCC were histologically normal and exhibited no clinical evidence of metastasis. IgG4-RD were diagnosed according to both the "Comprehensive diagnostic criteria for IgG4-related disease" 2 and "Diagnostic criteria for IgG4-DS" 4 . All patients with IgG4-RD showed characteristic histopathological findings including marked infiltration of IgG4-positive plasma cells, severe fibrosis, and formation of multiple ectopic GCs, and had never been treated with steroids or any other immunosuppressants. SS was diagnosed according to both the Research Committee on SS of the Ministry of Health and Welfare of the Japanese Government (1999) 25 and the American-European Consensus Group criteria for SS 26 . All patients with SS had lymphocytic infiltration in the LSGs, had no other autoimmune diseases, and had never been treated with steroids or any other immunosuppressants. There was no documented history of HIV, HTLV-1, hepatitis B virus or hepatitis C virus infection in any of the patients. None of the patients had evidence of malignant lymphoma at the time of the study Immunohistochemical analysis. For immunohistochemical analysis, 4 μ m formalin-fixed, paraffin-embedded SG sections were prepared and stained by a conventional avidin-biotin complex technique, as previously described 7 . Anti-ST2, -CD11c, -IL-4, and -IL-13 rabbit polyclonal antibodies were used to analyze ST2 (clone: HPA007406, Atlas, Stockholm), CD11c (clone: ab52632; Abcam, USA), IL-4 (clone: ab9622; Abcam, USA), and IL-13 (clone: HPA042421, Atlas, Stockholm) cytokines, respectively. Anti-IL-33, -CD68, -CD163, and -CD123 mouse monoclonal antibodies were used to analyze IL-33 (clone: Nessy-1, Enzo, Japan), CD123 (clone: NCL-CD123, Leica Biosystems, Germany), CD68 (clone: ab955; Abcam, USA), and CD163 (clone: NCL-CD163, Leica Biosystems, Germany) molecules, respectively. Sections were stained and evaluated according to previously described methods 27 . with DAPI for nuclei staining (Vector Laboratories, USA), and stored in the dark. Images were taken using a Keyence microscope (BZ-9000 series) with the background fluorescence level set using negative controls as no detected nuclei.
Double immunofluorescence of IL-33 and cell markers in
RNA extraction and complementary DNA (cDNA) synthesis. Total RNA was prepared from SGs by the acidified guanidinium-phenol-chloroform method as previously described 7, 28 . One microgram of the total RNA preparation was then used for the synthesis of cDNA. Briefly, RNA was incubated for 1 h at 42 °C with 20 U of RNasinribonuclease inhibitor (Promega, Madison, WI, USA), 0.5 μ g of oligo-1218 (Pharmacia, Uppsala, Sweden), 0.5 mM of each deoxyribonucleotide triphosphate (dNTP) (Pharmacia), 10 mM of dithiothreitol (DTT), and 100 U of RNase Reverse Transcriptase (Life Technologies, Gaithersburg, MD, USA).
Quantitative estimation of mRNA by real-time PCR. mRNA levels of the cytokines and chemokines in SGs were quantified by real-time PCR, using Light Cycler Fast Start DNA Master SYBR Green III (Roche Diagnostics, Mannheim, Germany) in a Light Cycler real-time PCR instrument (version 3.5; Roche Diagnostics). In this study, the cytokines and cluster of differentiations were IL-33, ST2, IL-4, IL-13, CD68, CD163, CD11c, and CD123. Target mRNA levels were expressed relative to β -actin as the housekeeping gene. The primer sequences used were as follows: β -actin, forward 5′ -GCA AAG ACC TGT ACG CCA AC-3′ , reverse 5′ -CTA GAA GCA TTT GCG GTG GA-3′ , 260 bp; IL-33, forward 5′ -ATG AGT CTC AAC ACC CCT CAA-3′ , reverse 5′ -CTG GTC TGG CAG TGG TTT TT-3′ , 155 bp; ST2 forward 5′ -ATT TGC ATG GCT TGA GAA GG-3′ , reverse 5′ -AGA GAA GCT CCC AGC AAA CA-3′ , 240 bp; IL-4 forward 5′ -AGC TGA TCC GAT TCC TGA AAC-3′ , reverse 5′ -TAC TCT GGT TGG CTT CCT TCA C-3′ , 90 bp; IL-13 forward 5′ -GGT CAA CAT CAC CCA GAA CC-3′ , reverse 5′ -TTT ACA AAC TGG GCC ACC TC-3′ , 240 bp; CD68 forward 5′ -TCA GAA TGC ATC CCT TCG AG-3′ , reverse 5′ -GAT GAG AGG CAG CAA GAT GG-3′ , 199 bp; CD163 forward 5′ -TGA TT CGG ACT TCT CTC TGG-3′ , reverse 5′ -ACT GGG CAG AGT GAA AGA TG-3′ , 168 bp; CD11c forward 5′ -TAC CTC ACC GGA CTC TGC TT-3′ , reverse 5′ -GGA GAA CTG CAT CAG GGA AA-3′ , 228 bp; CD123 forward 5′ -CCC AAC ATG ACT GCA AAG TG-3′ , reverse 5′ -CTA GAA GCA TTT GCG GTG GA-3′ , 200 bp. All analyses were performed in triplicate.
Cytokine determination by enzyme-linked immunosorbent assay (ELISA). IL4, IL-13, and IL-33
were measured by ELISA (IL-4: ab181426; Abcam, IL-13: ab178014; Abcam, and IL-33: GWB-SKR038; Gen Way Biotech, USA), according to the manufacturer's protocol. These results were compared with 12 non-smoking volunteers (healthy controls) who had no sicca or clinical or laboratory evidence of systemic disease. All analyses were performed in triplicate.
Statistics. Statistical significance of the differences between groups was determined using the following methods. A Mann-Whitney U test was used when populations were not normally distributed in the detection of mRNA expression levels 7, 28 . A non-parametric Spearman test was used for the correlation analysis. All statistical analyses were performed with JMP software, version 8 (SAS Institute, Cary, NC, USA). A P value less than 0.05 was considered statistically significant.
Results
Expression of IL-33, ST2, and Th2 cytokines in SGs. The mRNA expression levels of IL-33, ST2, and IL-4 in SGs from patients with SS and IgG4-RD were significantly higher than those in controls. Furthermore, the mRNA levels of ST2, IL-4, and IL-13 in patients with IgG4-RD were significantly higher than those from patients with SS (Fig. 1A) . The relationships between mRNA expression levels of IL-33 and Th2 cytokines (IL-4, IL-13) in Figure 1 . The expression of IL-33 and related molecules was higher in patients with IgG4-related disease (IgG4-RD). (A) mRNA expression levels of IL-33 and related molecules was examined in salivary glands (SGs) from controls (n = 10), and patients with Sjögren's syndrome (SS) (n = 10) and IgG4-RD (n = 7). Molecules were quantitatively estimated as described in the Methods section, and significant differences between groups were determined by the Mann-Whitney U test (*p < 0.05, **p < 0.01). (B) Correlation between mRNA expression levels of IL-33 and related molecules in SGs from controls, as well as patients with SS and IgG4-RD. Statistical significance of differences between groups was determined by Spearman's rank correlation (p < 0.05). SGs were examined, and the mRNA expression of IL-33 was positively correlated with Th2 cytokines in SGs from patients with IgG4-RD but not with Th2 cytokines in SGs from patients with SS and controls (Fig. 1B) . To evaluate the distribution of IL-33, ST2, and Th2 cytokines, representative histological findings in the SG specimens from patients with SS and IgG4-RD and from controls are shown in Fig. 1C . Expression of IL-33 was detected in all samples in the ductal epithelial cells, identified morphologically and indicated by black arrows. Interestingly, IL-33 was also detected in infiltrating lymphocytes around ectopic germinal centers (GCs) in patients with IgG4-RD, as indicated by yellow arrows in Fig. 1C . Expression of ST2, IL-4, and IL-13 was detected in infiltrating lymphocytes around ectopic GCs from patients with SS and IgG4-RD, but not in controls. In addition, patients with IgG4-RD showed strong infiltration of these positive cells in comparison to patients with SS.
Expression of IL-33-producing cells in SGs.
As IL-33 is considered to be produced by epithelial cells and antigen-presenting cells (APCs), such as macrophages and DCs 13 , we examined the expression of IL-33-producing cells in SGs from patients with SS and IgG4-RD, as well as in controls. The mRNA levels of CD68, CD163, CD11c, and CD123 were significantly higher in patients with IgG4-RD than in the two other evaluated groups (Fig. 2A) . Specimens were also immunohistochemically examined to clarify the distribution of IL-33-producing cells, including macrophagess (CD68, CD163), and DCs (CD11c, CD123), in the SGs from patients with SS and IgG4-RD, as well as controls. Expression of CD68 and CD163 was strongly detected around
Figure 2. Expression and localization of innate immune cells in SGs.
(A) mRNA expression levels of innate immune cells in SGs from controls (n = 10), and patients with SS (n = 10) and IgG4-RD (n = 7). Expression levels of innate immune cells markers for macrophages (CD68), M2 macrophages (CD163), mDC (CD11c), and pDC (CD123) were estimated quantitatively as described in the Methods section. Statistically significant differences between groups were determined by Mann-Whitney U tests (*p < 0.05, **p < 0.01). (B) Distribution of innate immune cells in SGs from representative controls and patients with SS and IgG4-RD. Counterstaining was performed with Mayer's hematoxylin (blue). Scale bars, 100 μ m. ectopic GCs in SGs from patients with IgG4-RD, whereas CD68 and CD163 were detected around ductal epithelial cells in patients with SS. Expression of CD11c was strongly detected in/around ectopic GCs in patients with IgG4-RD, whereas CD11c was detected around ductal epithelial cells in patients with SS. Finally, expression of CD123 was slightly detected in/around ectopic GCs in patients with IgG4-RD, but CD123 was rarely seen in patients with SS. All of these markers were rarely seen in controls (Fig. 2B) .
Co-localization of IL-33 and cell markers in SGs from patients with IgG4-RD.
To clarify which cells produced IL-33, double immunofluorescence staining with IL-33 (green) and CD68, CD163, CD11c, or CD123 (red) was performed. Using this approach, we observed that IL-33-positive cells co-localized with CD68-and CD163-positive cells, indicated by white arrows, and only partly co-localized with CD11c-or CD123-positive cells (Fig. 3) . Therefore, macrophages, especially M2 macrophages, might be responsible for the production of IL-33 in SGs from patients with IgG4-RD.
Serum concentration of IL-33 and Th2 cytokines. Recent study reported that serum IL-33 and ST2
were significantly elevated in pSS patients in comparison with healthy controls 18 . Therefore, we measured the serum concentration of IL-33 and Th2 cytokines (IL-4 and IL-13) in patients with SS, IgG4-RD, and healthy controls by ELISA. Serum IL-33 levels in patients with pSS were higher than that in controls (Fig. 4A) , and IgG4-RD showed the decrease in serum IL33 after steroid therapy (Fig. 4B) . On the other hand, there was no significant difference in serum IL-4 and IL-13 levels between IgG4-RD patients and controls (Supplementary Figure 1) .
Discussion
IgG4-RD is well known as a systemic disorder that is characterized by elevated serum IgG4, marked infiltration of IgG4-positive plasma cells, and severe fibrosis with hyperplastic eGCs in affected lesions. Although many basic studies on IgG4-RD have been reported in the past 10 years, the pathogenic mechanism of the disease remains unclear. Recent studies have reported that IgG4-RD is a Th2-dominant disease and that aberrant activation of the Th2 immune response plays a key role in its pathogenesis [6] [7] [8] 29, 30 . In this study, we focused on IL-33 as a recently identified cytokine that enhances Th2 cytokine production. Recent studies indicated the involvement of the IL-33/ST2 axis in the pathogenesis of pSS 18, 19 . They found that serum IL-33 and ST2 levels were increased in pSS patients and that IL-33 producing cells were mainly epithelial cells in SGs from patients with pSS. Our current data were consistent with these previous reports, and reveal that expression of IL-33 in SGs from patients with IgG4-RD was detected not only in ductal epithelial cells, but also around ectopic GCs. It is found that IL-33 was mainly expressed in epithelial cells and produced by a wide variety of cell types including DCs, macrophages, fibroblasts, mast cells, and osteoblasts 31 . Here, to confirm the IL-33-producing cells around ectopic GCs, we analyzed the expression of macrophages and DCs and found that IL-33 could be localized to M2 macrophages. In addition, mRNA expression of IL-33 was positively correlated with that of Th2 cytokines in patients with IgG4-RD. These results indicate that the majority of IL-33-producing cells in IgG4-RD might be M2 macrophages, which are deeply involved in the activation of Th2 immune responses.
With regard to DCs, recent studies that pDCs in SGs ware associated with the pathological processes of acute/ chronic salivary inflammation in SS and IgG4-RD 32, 33 . In our current study, we found that IL-33-positive cells partly co-localized with CD11c-or CD123-positive DCs in SGs from patients with IgG4-RD, but IL-33 and DCs were rarely seen in SS. Maria NI, et al. 34 divided pSS patients according to the mRNA expression of IFN type I in PBMC, and demonstrated that pDCs were detected in SGs from only IFN-positive pSS. Considering to these reports, our current data (Fig. 2B ) might be reflect to the results of IFN-negative pSS.
We previously examined M1 and M2 macrophage subsets in SGs from patients with SS, chronic sialoadenitis, and IgG4-RD, and indicated that the amount and frequency of M2 macrophages in patients with IgG4-RD were significantly higher than those in controls, as well as in patients with chronic sialoadenitis and SS. These findings were mirrored by other lesions in the LG, pancreas, pleura, and prostate gland from patients with IgG4-RD 27 . Furthermore, Fukui et al. 35 detected M2 macrophages expressing toll-like receptor 7 (TLR7) in patients with IgG4-related autoimmune pancreatitis. Alveolar macrophages are the primary source of increased IL-33 levels during infection, and an in vitro stimulation of these cells with a TLR7 agonist induces IL-33 expression 36 . In the current study, we also detected a number of SGs expressing TLR7 from patients with IgG4-RD. Further, these SGs were shown to co-localize with CD163-positive cells (Supplemental Fig. 2 ), indicating that M2 macrophages activated by the TLR7 pathway might play a crucial role in IgG4-RD as well as IgG4-related AIP.
In our previous study, gene expression in SGs from patients with IgG4-RD, chronic sialoadenitis and controls was analyzed via DNA microarrays. Using this approach, the macrophage receptor with collagenous structure (MARCO), one of the scavenger receptors 37 , was identified as a disease-associated molecule in patients with IgG4-RD. Moreover, immunohistochemical analysis has confirmed that the expression patterns of MARCO are similar to those of M2 macrophage marker CD163 10 . MARCO, a scavenger receptor expressed by macrophages 38 , has been reported to play an important role in the innate immune response by mediating ligand binding and phagocytosis. Further, this receptor can recognize various ligands including bacterial lipopolysaccharide (LPS), apoptotic cells, lung pathogens, environmental particles, and nanomaterials 39 . Taken together with the previous reports, the current results indicate that M2 macrophages may contribute to the initiation or maintenance of IgG4-RD via IL-33 production. We thus made the following hypothesis regarding the pathogenic process in IgG4-RD: M2 macrophages recognize certain exogenous or endogenous molecules through binding to pattern-recognition receptors, including TLR7 and MARCO. Following their binding to these receptors, M2 macrophages promote the production of IL-33, which precipitates an exaggerated Th2 immune responses and the pathology noted in IgG4-RD (Supplementary Figure 3) .
On the other hand, other Th subsets (regulatory T cells, T follicular helper (Tfh) cells, and CD4+ cytotoxic T lymphocytes) and innate immune cells (DCs and basophils) have recently received increasing attention with regard to the pathogenesis of IgG4-RD 29, 40, 41 . Maehara T, et al. 42 reported that the ratio of CD4+ GZMA+ CTLs in SMGs from patients with IgG4-DS correlated with serum IgG4 concentrations and the number of affected organs. Therefore, IgG4-RD might be initiated and progressed by the interconnected network of various Th subsets. A literature Summary on the etiology and pathogenesis of IgG4-DS and SS is shown in Table 2 .
In conclusion, we confirmed IL-33 overexpression in M2 macrophages clustered around ectopic GCs in SGs from patients with IgG4-RD. However, functional assays are needed to elucidate the mechanism of M2 macrophage-mediated IL-33 production. Although glucocorticoids are effective and the standard treatment for IgG4-RD, Yamamoto et al. 43 reported that almost half of patients with IgG4-RD experience disease relapse during long-term steroid therapy. A more thorough understanding of the role of M2 macrophages in IgG4-RD could lead to the establishment of a mouse model of IgG4-RD and to the eventual development of novel pharmacological strategies to interrupt IL-33/ST2 signaling as a further means of inhibiting disease initiation or progression.
• Th2 and regulatory immune reactions play a key role of IgG4 production in IgG4-RD.
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